NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, – Trademark Portfolio
Entity Type: 03
NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BCUREFUL. The owner is based in SILVER SPRING, MD.
8737 COLESVILLE ROAD
SILVER SPRING, MD 20910
Showing of trademarks Trademarks
Trademark Classifications
NATIONAL TUBEROUS SCLEROSIS ASSOCIATION,'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, have?
NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, file in?
NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 36 (Insurance & Financial). Class 35 covers advertising; business management; business administration; office functions.
What are NATIONAL TUBEROUS SCLEROSIS ASSOCIATION,'s most well-known trademarks?
NATIONAL TUBEROUS SCLEROSIS ASSOCIATION,'s registered trademark portfolio includes well-known marks such as BCUREFUL. These are among 1 currently registered trademark in the portfolio.
What is NATIONAL TUBEROUS SCLEROSIS ASSOCIATION,'s trademark registration success rate?
NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.